Clinical Trials on Blood Coagulation Disorders

Total 202131 results

RESCUe - RESeau Cardiologie Urgence / RESUVal -...
Hospices Civils de Lyon

Unknown

Accessibility of Prophylaxis and On-demand Treatment for Persons With Haemophilia and Other Coagulation Deficiencies (PHAREO)

Health Services Accessibility | Blood Coagulation Factor Deficiencies

France
CSL Behring

Completed

Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency

Congenital Coagulation Factor VII Deficiency

Netherlands, Norway
Hospitales Universitarios Virgen del Rocío

Completed

Perioperative Coagulopathy in Patients Undergoing Cytoreductive Surgery and HIPEC Intraperitoneal Chemotherapy (HIPEC) (HIPEC-COAG)

Coagulation Disorder | Carcinomatosis

Spain
BioMarin Pharmaceutical

Active, not recruiting

Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 (GENEr8-AAV5+)

Hemophilia A | Gene Therapy | Blood Disorder | Clotting Disorders

Taiwan, Korea, Republic of, United Kingdom, South Africa
University Hospital, Motol

Completed

ROTEM Versus aPTT/PT in Pediatric Surgery

Coagulation Defect; Bleeding
Meghan McCormick

Terminated

A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia

Thrombocytopenia | Pediatric Cancer | Hemostatic Disorder | Coagulation Defect; Acquired

United States
Entegrion, Inc.

Completed

Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers

Coagulation Defects

United States
Kyowa Kirin Co., Ltd.

Completed

An Open-label Study of KW-3357 (3357-004)

Disseminated Intravascular Coagulation (DIC)

Japan
HemoSonics LLC

Completed

Quantra QStat Sample Type Comparison

Coagulation Defect; Bleeding

United States
Oregon Health and Science University

Completed

Motor Proficiency of People With Bleeding Disorders Using the BOT-2 (TM)

Hemophilia

United States
Augusta University

Completed

Thromboelastogram in Postdelivery Preeclamptic Patients

Pregnancy Complications | Coagulation Disorder | Preeclampsia

United States
HemoSonics LLC

Completed

Quantra QPlus Sample Type Comparison

Coagulation Defect; Bleeding

United States
Tianjin Medical University General Hospital

Recruiting

Application of a New Type of Whole Blood Coagulation Time Measurement in Evaluating the Hypercoagulable State of Malignant Tumors (GCTHCM)

Neoplasm Metastasis | Venous Thromboembolism | Blood Coagulation Disorder With Shortened Coagulation Time (Disorder)

China
Novo Nordisk A/S

Completed

A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A (pathfinder8)

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Spain, Switzerland, Taiwan, Turkey, United Kingdom, Croatia, Germany, Brazil, France, Japan, Australia, Hungary, Israel, Korea, Republic of, Lithuania, Portugal, Ukraine, Greece, Italy, Denmark, Norway, Canada and more
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A (guardian™4)

Congenital Bleeding Disorder | Haemophilia A

United States, Denmark, Austria, Spain, Japan, Brazil, Algeria, Lithuania, Portugal, Russian Federation, Serbia, Turkey, Greece, Hong Kong, Puerto Rico, Hungary, China, Poland
Novo Nordisk A/S

Completed

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A (pathfinder™5)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Switzerland, Malaysia, Brazil, Canada, Japan, United Kingdom, Israel, Portugal, Ukraine, Greece, Lithuania, Puerto Rico, Turkey, Italy
Novo Nordisk A/S

Completed

Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. (pathfinder™3)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, United Kingdom, Croatia, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Italy, Japan, Norway, Bulgaria
Novo Nordisk A/S

Completed

Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A (alleviate 1)

Congenital Bleeding Disorder | Haemophilia A

United States, Austria, Serbia, Germany, Japan, France
Novo Nordisk A/S

Completed

Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 (mentor™2)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

France, United States, Israel, Spain, Switzerland, Germany, Canada, Japan, United Kingdom, Italy, Finland, Austria
Novo Nordisk A/S

Completed

Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Austria, Spain, Poland, United Kingdom, Croatia, Germany, Malaysia, Australia, France, Israel, Thailand, Ukraine, Turkey
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A (guardian™ 3)

Congenital Bleeding Disorder | Haemophilia A

United States, Macedonia, The Former Yugoslav Republic of, Serbia, Malaysia, Brazil, Turkey, Lithuania, Russian Federation, Italy, Japan, Poland, Puerto Rico, Taiwan
Novo Nordisk A/S

Completed

A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543

Congenital Bleeding Disorder | Haemophilia A

Japan
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Epidemiology and Immunology of Hemophilia A Inhibitors

Hemophilia A | Blood Disease
Emory University

Completed

High-Shear Microfluidic Thrombosis Assay

Coagulation Defects, Other and Unspecified

United States
Haemnet
Hemab ApS

Recruiting

The Lived Experience of People With Von Willebrand Disease (VWD360)

Von Willebrand Diseases

United Kingdom
Octapharma

Completed

Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease

Von Willebrand Disease

United States, Canada, Sweden, Spain, Uruguay, United Kingdom, Portugal, Argentina, Czechia, Germany
Erasmus Medical Center
Shire; CSL Behring; Stichting Haemophilia (Dutch Haemophilia Foundation)

Unknown

Von Willebrand Disease in the Netherlands (WiN-Pro)

Von Willebrand Disease

Netherlands
CSL Behring

Completed

Study of Voncento® in Subjects With Von Willebrand Disease

Von Willebrand Disease

Poland, Germany, Austria, Greece, United Kingdom
Weill Medical College of Cornell University

Withdrawn

Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)

Von Willebrand Disease

United States
The University of Texas Health Science Center,...
The ZLB Behring Foundation

Terminated

Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle

Von Willebrand Disease

United States
Centro Hospitalar Tondela-Viseu
Portuguese IBD Group

Completed

Inflammatory Bowel Disease and Thromboembolic Events

Inflammatory Bowel Diseases | Coagulation Disorder | Thromboembolism

Portugal
Qilu Hospital of Shandong University

Recruiting

The Proactive Diagnostic Value of Hemostatic Biomarkers in Disseminated Intravascular Coagulation

Disseminated Intravascular Coagulation

China
McMaster University
Epitome Pharmaceuticals

Terminated

Randomized Controlled Feasibility Trial of the Fearon Algorithm to Improve Management of Unstable Warfarin

Hypoprothrombinemia

Canada
Novo Nordisk A/S

Completed

Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients

Congenital Bleeding Disorder | Haemophilia A

Mexico
Novo Nordisk A/S

Terminated

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (explorer™2)

Healthy | Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United Kingdom, France, Germany
Novo Nordisk A/S

Completed

Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A (guardian ™9)

Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United States, Germany, Serbia, Taiwan, Bulgaria
Novo Nordisk A/S

Completed

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A (pathfinder™7)

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Spain, Germany, France, Denmark
Enzyre B.V.
Indiana Hemophilia & Thrombosis Center

Not yet recruiting

Case and Use Scenario Study to Gain Knowledge on the User Needs for a Medical Device for Hemophilia A Monitoring

Hemophilia A

United States
Hospices Civils de Lyon

Recruiting

EVALUATION OF THE OVERALL HAEMOSTATIC CAPACITY OF MIM8 WITH GLOBAL HAEMOSTASIS ASSAYS AND FIBRIN CLOT ULTRASTRUCTURE (Mim8-TGT)

Hemophilia A

France
Biocad

Recruiting

A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A (EDELWEISS)

Hemophilia A

Russian Federation
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Hemophilia A

Spain, Canada, United States, New Zealand, Italy, Poland
University Hospital, Grenoble

Recruiting

Impact of Emicizumab on Activated Clotting Time Using the i-STAT Alinity Analyzer (EMISTAT)

Hemophilia A

France
Centre Hospitalier Universitaire de Saint Etienne

Recruiting

In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients

Hemophilia

France
World Federation of Hemophilia

Not yet recruiting

The World Federation of Hemophilia Gene Therapy Registry (WFH GTR)

Hemophilia
Prof. Dr. Dr. Thomas Hilberg

Recruiting

Clinical and Health-related Outcome of rFVIIIFc Prophylaxis (CLHEAR)

Hemophilia A

Germany
Brugmann University Hospital

Recruiting

Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?

Hemophilia

Belgium
Swedish Orphan Biovitrum

Active, not recruiting

A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health (A-MORE)

Hemophilia A

Spain, Germany, Czechia, Italy, Estonia, Finland, Greece, Netherlands, Saudi Arabia, Slovenia, Sweden, Switzerland, United Kingdom
Takeda

Completed

A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.

Hemophilia A

Japan
Takeda
Takeda Pharma Korea Co. Ltd.

Completed

Post Marketing Surveillance Study for ADYNOVATE in South Korea

Hemophilia A

Korea, Republic of
Eli Lilly and Company
Sigilon Therapeutics, Inc.

Terminated

Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A

Hemophilia A

United Kingdom, United States

Clinical Trials on Blood Coagulation Disorders

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations